# Turner Syndrome

Confirm suspected Turner syndrome with appropriately extensive cytogenetic analysis, define mosaicism and Y-chromosome material, then initiate phenotype-directed cardiovascular, renal, endocrine, growth, reproductive, hearing, and neurodevelopmental surveillance across the lifespan.

**Clinical question:** How should physicians confirm Turner syndrome and prioritize lifelong evaluation of its highest-impact complications?

Updated: 2026-08-24T18:06:29.250725+00:00

## What matters in practice
- Order peripheral-blood chromosome analysis for unexplained short stature in girls, delayed puberty, primary ovarian insufficiency, infertility, or compatible congenital findings; Turner syndrome may present with isolated short stature and minimal somatic findings. [1][22][23]
- Analyze at least 30 peripheral-blood metaphases when evaluating suspected Turner syndrome; this detects approximately 10% mosaicism with 95% confidence. [16][23]
- If the karyotype is normal but clinical suspicion remains high, pursue expanded metaphase analysis and/or testing of another tissue because blood testing can miss mosaicism. [14][23]
- Identify Y-chromosome material because 45,X/46,XY mosaicism has variable phenotypes and is associated with a recommendation for prophylactic gonadectomy at diagnosis. [14]
- Before pregnancy or assisted reproduction, obtain comprehensive cardiovascular assessment and counsel regarding elevated aortic-dissection risk, particularly with aortic dilation, bicuspid aortic valve, coarctation, or hypertension. [3][10][24]

## When to order cytogenetic testing

Do not require classic physical findings before testing.

Order chromosome analysis when a patient has otherwise unexplained short stature, delayed or absent puberty, primary ovarian insufficiency, infertility, or a compatible congenital cardiovascular or renal phenotype. The phenotype is heterogeneous, may evolve over time, and may be limited to growth impairment; Turner syndrome affects approximately 25 to 50 per 100,000 females. [19][22][23]

In girls with height below the third percentile, include Turner syndrome in the initial genetic differential even when routine blood counts, inflammatory markers, renal function, liver enzymes, and thyroid testing are normal. A normal screening laboratory profile does not exclude Turner syndrome, and diagnostic delay can defer growth treatment and recognition of comorbidities. [1]

Prenatal findings that should prompt diagnostic counseling include increased nuchal translucency, cystic hygroma, hydrops, abnormal ductus venosus flow, or low pregnancy-associated plasma protein A. Cell-free DNA is a screening test rather than definitive confirmation; establish the fetal diagnosis with chorionic villus sampling or amniocentesis when clinically indicated. [23]
- After a prenatal cytogenetic result suggestive of Turner syndrome, obtain postnatal peripheral-blood chromosome analysis because prenatal testing may not define the final constitutional karyotype, especially with mosaicism. [23]
- Consider alternative diagnoses when the phenotype resembles Turner syndrome but cytogenetic testing is unrevealing; Noonan syndrome is a relevant phenocopy in a child with short stature and compatible somatic findings. [21]

*Clinical presentation determines the appropriate route to definitive cytogenetic diagnosis. [22][23]*

| Presentation | Next diagnostic action | Decision consequence |
| --- | --- | --- |
| Short stature, pubertal delay, reproductive concern, or compatible congenital anomaly | Peripheral-blood karyotype with at least 30 metaphases. [16][23] | Detects approximately 10% mosaicism with 95% confidence and establishes the initial constitutional result. [16][23] |
| Strong phenotype with nondiagnostic blood karyotype | Request additional metaphases and consider cytogenetic testing of another tissue. [14][23] | Low-level or tissue-specific mosaicism may be missed in standard blood analysis. [14][23] |
| Prenatal screen or ultrasound suspicion | Use chorionic villus sampling or amniocentesis for prenatal confirmation; repeat chromosome analysis from peripheral blood after birth. [23] | Prenatal results may incompletely characterize mosaicism. [23] |

## Interpret mosaicism and Y-chromosome material clinically

A karyotype is a risk-stratification result, not merely a diagnostic label.

Peripheral-blood leukocyte karyotyping is the first diagnostic test for Turner syndrome. The laboratory standard historically includes analysis of at least 20 cells for mosaicism, while analysis of 30 metaphases provides approximately 95% confidence for detecting a 10% mosaic cell line. [15][16][23]

Do not infer absence of Turner-associated disease from a mild phenotype or a low proportion of 45,X cells in blood. Women with 45,X mosaicism can have average height and typical timing of menarche and menopause, but karyotype-phenotype correlations remain insufficiently consistent to individualize surveillance solely from the blood mosaic fraction. [8][15]

When 45,X/46,XY mosaicism or other Y-chromosome material is identified, assess gonadal anatomy and involve pediatric/adult endocrinology, gynecology, urology as appropriate, and genetics. Phenotypes range from mixed gonadal dysgenesis and ambiguous genitalia to a Turner phenotype with normal female secondary sexual characteristics; prophylactic gonadectomy is recommended at diagnosis because of gonadal tumor risk. [14]
- Use FISH analysis of a larger number of cells or another tissue when the phenotype and a limited conventional karyotype conflict; a reported case with an initial five-cell 46,XY result was reclassified after 50-cell FISH identified 18% 45,X cells. [14]
- In an older patient, interpret very low-level 45,X mosaicism cautiously: in women older than 50 years, less than 5% 45,X cells may represent age-related X-chromosome loss rather than constitutional Turner syndrome. [22]

*Cytogenetic pattern changes the immediate management pathway. [14][15][22][23]*

| Finding | Interpretation | Next step |
| --- | --- | --- |
| 45,X or structural X-chromosome abnormality | Supports Turner syndrome in the appropriate clinical setting. [23] | Begin multidisciplinary baseline assessment for cardiovascular, renal, endocrine, hearing, vision, bone, growth, and reproductive complications. [14][19] |
| 45,X/46,XX mosaicism | May have attenuated phenotype, but blood mosaic fraction alone does not reliably determine complication risk. [8][15] | Use phenotype-directed surveillance rather than withholding assessment because of an apparently mild presentation. [15] |
| 45,X/46,XY mosaicism or Y-chromosome material | Phenotype is variable and includes gonadal dysgenesis. [14] | Refer for gonadal assessment and plan prophylactic gonadectomy at diagnosis. [14] |
| Normal blood karyotype with persistent high suspicion | Does not exclude tissue-limited mosaicism. [14][23] | Expand metaphase analysis and consider FISH or testing of buccal or other tissue. [14][15][23] |

## Establish the organ-specific risk profile at diagnosis

Use diagnosis to trigger targeted evaluation before symptoms emerge.

At diagnosis, organize care around congenital cardiovascular disease, aortic disease, renal anomalies, ovarian insufficiency, growth, thyroid and other autoimmune disease, hearing, vision, skeletal health, metabolic risk, and neurodevelopmental function. Turner syndrome is associated with congenital cardiovascular and renal anomalies, early sensorineural hearing loss, autoimmune thyroiditis and celiac disease, and a characteristic neurodevelopmental profile. [19][22]

Prioritize cardiovascular characterization because bicuspid aortic valve, coarctation of the aorta, aortic dilation, and hypertension materially alter pregnancy counseling and aortic risk. In a pregnancy cohort of thoracic aortic disease, most published Turner-associated dissections occurred in patients with congenital or acquired cardiovascular abnormalities, including bicuspid aortic valve, coarctation, or aortic dilation. [3]

Use a multidisciplinary longitudinal care model rather than an isolated genetics consultation. Guidelines frame Turner syndrome as a lifelong multisystem condition requiring coordinated pediatric-to-adult transition, with diagnostic/genetic, growth/developmental, cardiovascular, transition/adult-care, and comorbidity domains addressed explicitly. [19][20]
- Document blood pressure and identify pre-existing hypertension, particularly before conception; among pregnancies in women with coarctation, pre-existing hypertension was reported in 27.1%. [2]
- Assess pubertal development and ovarian function early enough to plan hormone replacement and fertility counseling; premature ovarian insufficiency and delayed puberty are recognized manifestations. [22]
- Screen for hearing, vision, thyroid disease, celiac disease, metabolic complications, renal anomalies, bone health, and neurodevelopmental needs as part of the initial phenotype assessment. [14][19][22]

*Baseline assessment should be phenotype-directed but cover high-impact Turner-associated systems. [14][19][22]*

| Clinical domain | Why it changes management | Immediate action |
| --- | --- | --- |
| Cardiovascular and aortic disease | Bicuspid aortic valve, coarctation, aortic dilation, and hypertension affect dissection risk and reproductive eligibility. [3][24] | Obtain formal cardiovascular assessment before pregnancy or assisted reproduction. [10][24] |
| Gonadal function and Y material | Delayed puberty, primary ovarian insufficiency, infertility, and gonadal dysgenesis require reproductive planning; Y material prompts gonadectomy planning. [14][22] | Assess pubertal and reproductive status; refer for gonadal management if Y-chromosome material is present. [14] |
| Growth | Short stature may be the sole presenting feature and delayed recognition can delay treatment. [1] | Refer early for pediatric endocrine assessment when growth failure is identified. [1][13] |
| Renal, endocrine, hearing, vision, bone, metabolic, and neurodevelopmental status | These are recognized Turner-associated morbidity domains. [14][19][22] | Establish baseline specialty screening and transition plan. [19][22] |

## Act early on growth, pubertal failure, and reproductive planning

Timing matters because growth and reproductive options narrow with age.

Refer children promptly for growth-hormone evaluation after diagnosis or when Turner syndrome is strongly suspected. The 2016 international guideline recommended starting growth hormone at approximately 4 to 6 years of age and preferably before 12 to 13 years, supporting early rather than deferred referral when linear growth is impaired. [13]

Assess spontaneous pubertal progression and ovarian function rather than assuming uniform gonadal failure. Premature ovarian insufficiency, delayed puberty, and infertility occur within the recognized Turner phenotype, while some women with 45,X mosaicism undergo menarche and menopause at average ages. [8][22]

Provide reproductive counseling before pregnancy attempts or assisted reproductive technology. International guidance supports comprehensive preconception assessment in women with Turner syndrome, and pregnancy—often requiring assisted reproductive technology—is associated with increased risk of aortic dissection. [10][24]
- Do not use a blood mosaic percentage alone to promise preserved ovarian function or low cardiovascular risk; tissue distribution and phenotype vary. [8][15]
- For patients considering pregnancy, obtain cardiovascular evaluation before treatment decisions involving donor oocytes, in vitro fertilization, or other assisted reproductive approaches. [10][14][24]
- Involve maternal-fetal medicine and adult congenital heart disease/aortopathy expertise when cardiovascular abnormalities, hypertension, or aortic dilation are present before conception. [3][10][24]

### Pregnancy counseling and delivery planning

Counsel that aortic events are the central catastrophic maternal complication. Published Turner-associated dissection cases have largely involved bicuspid aortic valve, coarctation, or aortic dilation; therefore, these findings should shift counseling toward individualized high-risk pregnancy assessment rather than routine obstetric management. [3][24]

Available contemporary cohort data are limited. In one thoracic aortic disease cohort, none of 16 women with Turner syndrome had a cardiovascular event, although one had ascending aortic diameter 42 mm with an aortic size index of 21.6 mm/m², four had preconception hypertension, and one had bicuspid aortic valve. These observations do not eliminate risk in patients with adverse aortic phenotypes. [3]
- Avoid interpreting cesarean delivery as universally required solely by a Turner diagnosis; cesarean delivery was common in one cohort, but indications among many Turner participants were unclear. [3]
- Escalate pregnancy planning when hypertension, bicuspid aortic valve, coarctation, or aortic dilation is present. [3][24]

*Reproductive decisions should follow cardiovascular phenotyping, not diagnostic labeling alone. [3][8][10][24]*

| Decision point | Risk discriminator | Action |
| --- | --- | --- |
| Child with impaired linear growth | Turner syndrome diagnosis or high suspicion with short stature. [1][13] | Refer for growth-hormone assessment early; guidelines cited initiation at approximately 4 to 6 years and preferably before 12 to 13 years. [13] |
| Delayed puberty or primary ovarian insufficiency | Absent or inadequate pubertal development, reproductive concern, or infertility. [22] | Assess ovarian and pubertal status and coordinate endocrine-reproductive counseling. [22] |
| Considering pregnancy or assisted reproduction | Any Turner syndrome phenotype, especially hypertension, bicuspid valve, coarctation, or aortic dilation. [3][10][24] | Complete preconception cardiovascular assessment and multidisciplinary counseling before conception. [10][24] |

## Maintain surveillance through transition and adulthood

The diagnostic karyotype should remain visible in adult problem lists and pregnancy planning.

Transition planning should explicitly transfer responsibility for cardiovascular surveillance, reproductive and endocrine care, hearing and vision assessment, metabolic and autoimmune screening, bone health, and neurodevelopmental support. Turner syndrome guidelines identify transition and adult care as a dedicated domain because complications persist and may first become clinically consequential after pediatric follow-up ends. [19][20]

Reassess cardiovascular status before any pregnancy-related decision, even in patients with prior uncomplicated health or a mosaic karyotype. In the reported thoracic aortic disease cohort, Turner participants included patients with preconception hypertension, bicuspid aortic valve, and documented aortic dilation despite no cardiovascular events during the observed pregnancies. [3]

Treat new clinical findings as phenotype changes requiring targeted reassessment rather than as evidence against the diagnosis. Development of hypertension, hearing loss, thyroid disease, celiac disease, metabolic complications, or reproductive problems should prompt condition-specific management within the broader Turner syndrome care plan. [19][22]
- Keep congenital heart disease and aortic-risk history prominent in the adult chart, particularly before prescribing fertility treatment or clearing pregnancy. [3][10][24]
- Revisit the genetic result when the phenotype is discordant with prior testing, particularly if the original study analyzed few cells or did not clarify possible Y-chromosome material. [14][16]
- Use coordinated endocrinology, cardiology, genetics, primary care, and reproductive care rather than serial unconnected referrals. [19][22]

*Follow-up should be triggered by changing risk states rather than a fixed one-time diagnostic evaluation. [3][14][19][22][24]*

| Trigger | Clinical concern | Next action |
| --- | --- | --- |
| Pregnancy planning or assisted reproduction | Aortic dissection risk, especially with structural cardiovascular disease or hypertension. [3][10][24] | Repeat comprehensive preconception cardiovascular assessment and multidisciplinary counseling. [10][24] |
| Pubertal failure, amenorrhea, or infertility | Premature ovarian insufficiency or gonadal dysgenesis. [22] | Reassess reproductive endocrine status and provide fertility counseling. [22] |
| Discordant phenotype or limited initial cytogenetic study | Undetected mosaicism or Y-chromosome material. [14][23] | Request expanded cytogenetic analysis and consider FISH or another tissue. [14][15][23] |
| New hearing, thyroid, gastrointestinal, metabolic, skeletal, or neurodevelopmental concern | Recognized multisystem Turner-associated morbidity. [19][22] | Perform targeted condition-specific evaluation while maintaining lifelong coordinated care. [19][22] |

## References
1. Testing the Tests — jamanetwork.com — https://jamanetwork.com/journals/jamapediatrics/fullarticle/204152
2. Pregnancy outcomes in women with aortic coarctation — heart.bmj.com — https://heart.bmj.com/content/heartjnl/early/2020/10/29/heartjnl-2020-317513.full.pdf
3. Pregnancy outcome in thoracic aortic disease data from the ... — heart.bmj.com — https://heart.bmj.com/content/heartjnl/early/2021/01/18/heartjnl-2020-318183.full.pdf
4. Aortic dilatation and outcome in women with Turner ... — heart.bmj.com — https://heart.bmj.com/content/early/2018/10/27/heartjnl-2018-313716.responses?versioned=true
5. 73 Maternal and Fetal Outcomes in Women with Aortopathy — heart.bmj.com — https://heart.bmj.com/content/102/Suppl_6/A53
6. Caring for individuals with a difference of sex development (DSD): a Consensus Statement | Nature Reviews Endocrinology — www.nature.com — https://www.nature.com/articles/s41574-018-0010-8
7. Laboratory guideline for Turner syndrome | Genetics in Medicine — www.nature.com — https://www.nature.com/articles/gim20108
8. Mosaic Turner syndrome shows reduced penetrance in an adult population study | Genetics in Medicine — www.nature.com — https://www.nature.com/articles/s41436-018-0271-6
9. ACMG Statements and Guidelines — www.nature.com — https://www.nature.com/collections/afebagafci
10. Reproductive health in Turner syndrome: A narrative review — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/pd.6261
11. Cardiovascular risk in Turner syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2174204918302502
12. Laboratory guideline for Turner syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1098360021020852
13. Growth Hormone Treatment to Final Height in Turner ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0149291823004770
14. Mosaic Turner Syndrome Presenting with a 46,XY Karyotype — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2019/3719178
15. Genetic counseling for women with 45,X/46,XX mosaicism: Towards more personalized management — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1769721221000069
16. Diagnosis of Turner Syndrome in the Eighth Decade of Life — academic.oup.com — https://academic.oup.com/jcemcr/article/2/6/luae104/7696981
17. Whole-Exome Sequencing for Diagnosis of Turner Syndrome — academic.oup.com — https://academic.oup.com/jcem/article/102/5/1529/2952610
18. Cell-free DNA screening positive for monosomy X: clinical ... — www.ajog.org — https://www.ajog.org/article/S0002-9378(22)00540-3/abstract
19. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting - PubMed — ncbi.nlm.nih.gov — https://ncbi.nlm.nih.gov/pubmed/28705803
20. Clinical Practice Guidelines for the Care of Girls and Women With Turner Syndrome — publications.aap.org — https://publications.aap.org/pediatrics/article/140/5/e20172626/37754/Clinical-Practice-Guidelines-for-the-Care-of-Girls
21. Cover Page for Protocol — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/35/NCT05723835/Prot_000.pdf
22. Turner Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69c345d0f7dc4e68e786b1f9
23. Turner Syndrome - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK554621
24. 2018 AHA/ACC Guideline for the Management of Adults ... — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.1161%2FCIR.0000000000000603&link_type=DOI

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.